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Metastatic melanoma is a highly aggressive disease.
Recent progress in immunotherapy (IT) and targeted
therapy (TT) has led to significant improvements in
response and survival rates in metastatic melanoma
patients. The current project aims to determine the benefit
of the introduction of these new therapies in advanced
melanoma across several regions of Switzerland. This is a
retrospective multicenter analysis of 395 advanced
melanoma patients treated with standard chemotherapy,
checkpoint inhibitors, and kinase inhibitors from January
2008 until December 2014. The 1-year survival was 69%
(n= 121) in patients treated with checkpoint inhibitors (IT),
50% in patients treated with TTs (n= 113), 85% in the
IT+ TT group (n= 66), and 38% in patients treated with
standard chemotherapy (n= 95). The median overall
survival (mOS) from first systemic treatment in the entire
study cohort was 16.9 months. mOS of patients treated
either with checkpoint or kinase inhibitors (n= 300,
14.6 months) between 2008 and 2014 was significantly
improved (P<0.0001) compared with patients treated with
standard chemotherapy in 2008–2009 (n= 95, 7.4 months).
mOS of 61 patients with brain metastases at stage IV was
8.1 versus 12.5 months for patients without at stage IV
(n= 334), therefore being significantly different
(P= 0.00065). Furthermore, a significant reduction in
hospitalization duration compared with chemotherapy was
noted. Treatment with checkpoint and kinase inhibitors
beyond clinical trials significantly improves the mOS in real
life and the results are consistent with published
prospective trial data. Melanoma Res 27:358–368
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Introduction
Historically, metastatic melanoma shows a poor prog-
nosis, with a median overall survival (mOS) of less than
1 year and an overall 5-year mortality close to 90% [1].
Although surgery and irradiation play a role in the treat-
ment of low burden metastatic disease, systemic therapy
is the mainstay for most advanced melanoma patients.
Since 1972 and until recently, cytotoxic chemotherapy
with dacarbazine has been considered the standard of
care in advanced melanoma patients, with an objective
response rate in a pooled analysis of 23 randomized
clinical trials of 15% [2].
Fortunately, with the development of targeted therapy
(TT) and immunotherapy (IT) in the past few years, the
standard of care for patients with advanced melanoma has
improved considerably [3–11]. The introduction and
approval of these new treatment options led to a radical
and promising change in the treatment landscape and in
the outcome of advanced melanoma patients [3,4,6–12].
Approximately 50% of all melanomas harbor BRAF
mutations, of which 75% are mutations of BRAF V600E,
representing a promising target in melanoma therapy
[13–17]. Vemurafenib (registered as Zelboraf), a selective
BRAF-inhibitor (BRAFi), was the first TT agent on the
melanoma market showing a statistically significant
improvement both in overall and in progression-free
survival (OS, PFS) of advanced melanoma in patients
harboring the BRAF V600 mutation [18]. However,
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responses are limited because of acquired drug resistance
[13,19–21]. Cotargeting the kinase downstream of BRAF
in the MAPK-pathway by a combination of MEK and
BRAF inhibition delays the emergence of resistance,
reduces the cutaneous side effects caused by paradoxical
activation of the MAPK-pathway, and significantly
improves the OS and PFS compared with vemurafenib or
dabrafenib alone [7,13]. Although monotherapy with a
selective MEK inhibitor (MEKi) in BRAF mutant
melanoma appears to be less efficient than BRAF inhi-
bition [8,13,22], it shows promising results in the NRAS
mutant melanoma population [23]. Currently, BRAFi and
MEKi combination treatment belongs to the ‘New Gold
Standard’ for BRAF mutant metastatic melanoma [24,25].
Besides being mutagenic, melanoma is considered to be a
highly immunogenic tumor on the basis of clinical
responses and neoantigen generation [26,27]. Ipilimumab
(registered as Yervoy; Bristol Meyers Squibb, New York,
New York, USA), a fully human monoclonal antibody,
blocks CTLA-4, thereby permitting uncontested T-cell
proliferation and antitumor immunity [6,12,28]. It was
the first agent to show a statistically significant benefit in
OS in stage IV melanoma patients both in a first-line and
in a second-line setting [6]. Recently, checkpoint inhi-
bitors interacting with programmed cell death (PD-1)
receptor, which is involved in reduction of autoimmunity,
changed the fatal history of the disease once again,
showing remarkable responses as well as prolonged OS
[29–32]. PD-1-antibodies alone or in combination with
ipilimumab have shown a higher response rate than ipi-
limumab monotherapy [8,27,33–37]. Many other combi-
nations interacting with immune checkpoints are
currently being investigated in clinical trials.
The aim of the current study was to evaluate the out-
come of stage IV melanoma patients across Switzerland
and confirm the longitudinal survival change after the
introduction of IT and TT in a real-life setting using a
registered-patient cohort standardized database (Swiss
Melanoma Registry).
Patients and methods
Patient selection and data acquisition
The study cohort included patients with stage IV meta-
static melanoma treated at the Dermatology Department
of the University Hospital Zurich, the Department of
Medical Oncology of the University Hospital Lausanne,
and the Department of Medical Oncology at the
Cantonal Hospital Graubünden Chur between January
2008 and December 2014. Stage IV disease was defined
according to the current American Joint Committee on
Cancer staging system.
Patients were divided into two groups according to the
first received treatment during the above period: standard
chemotherapy treated between 2008 and 2009 (reference)
versus the TT or the IT group from 2008 until 2014. In this
period, vemurafenib (Zelboraf, 960mg twice daily; Roche,
Basel, Switzerland) and ipilimumab (Yervoy, 3mg /kg) were
approved by Swiss authorities for the treatment of metastatic
melanoma, whereas anti-PD-1 (2mg /kg) treatment was only
accessible in an expanded-access program (EAP). Patients
treated with chemotherapy before the approval of TT or IT
were still included in the study cohort. In addition, the analysis
included antecedent data from 60 patients (15% of the entire
study cohort) in the following clinical trials: NCT01511913,
NCT01668784, NCT01320085, NCT01436656, NCT0121
3472, NCT01597908, NCT01682083, NCT01307397, and
NCT01704287.
All advanced melanoma patients at the University
Hospital Zurich as well as those from Department of
Medical Oncology at the Cantonal Hospital Graubünden
Chur and Department of Medical Oncology of the
University Hospital Lausanne who fulfilled the defined
inclusion criteria were registered anonymously into a
standardized clinical database. Information was retro-
spectively collected by reviewing the patient’s electronic
medical files. Before analysis, clinical information was
anonymized and deidentified. Standard anonymous data
collection on the course of disease after the diagnosis of
first distant metastases included treatment, development
of new metastases, and survival status. Epidemiological,
clinicopathological, laboratory, and molecular parameters
were also collected. Data were classified with dichot-
omous variables (yes or no) or coded with the number of
treatments and metastatic sites.
The local ethics committee approved written informed
consent for tissue storage including retrospective analysis
with collection of clinical/laboratory/histological infor-
mation before collection (Kantonale Ethikkommission
Zürich, Biobank/Sammlung von Tumorgewebe, KEK-
ZH-Nr. 647, 800).
Definition of baseline and endpoints
The primary endpoint of the study was the percentage of
patients surviving 1 year after being treated with standard
chemotherapy (reference group) between 2008 and 2009
or with IT or TT from 2008 until 2014. The secondary
endpoints included differences in mOS or PFS after the
introduction of IT and TT as well as in mOS of patients
with or without brain metastases at stage IV disease or
those with and without brain metastases during the
course of treatment. Furthermore, we analyzed survival
with respect to lactate dehydrogenase (LDH) levels and
hospitalization time (calculated in days) reflecting the
treatment-associated costs.
OS was defined as the time (months) from treatment initiation
to death, with censoring on the last known alive date.
Statistical analysis
Descriptive statistics are presented as percentages of total
for categorical variables and as median for continuous and
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ordinal variables. For the entire cohort, OS was estimated
with the Kaplan–Meier survival curves. Patients who
were alive at the end of the study period were censored
at the date of last follow-up. For survival time, summary
measures include the mOS and 95% confidence interval
(CI). The log-rank test was used to compare the survival
time between treatment groups. A Cox proportional hazards
model was used to estimate the adjusted hazard ratio (HR).
P-value less than 0.05 was considered statistically significant.
The analysis was carried out using R [38].
Results
Patient characteristics
Data of 442 American Joint Committee on Cancer Stage
IV melanoma patients, who received systemic treatment
for the disease from January 2008 until December 2014,
were collected in the electronic database.
A total of 395 fulfilled the inclusion criteria and were
subanalyzed according to their treatment protocol. Two
hundred and thirty-nine (60.5%) patients were men and
156 (39.5%) patients were women; the median age at first
diagnosis was 57 years (range: 13.6–88.5 years). Two
hundred and eighty-two (71.4%) patients had died by
December 2014 and of the 113 patients still alive, 11
were lost to follow-up.
One hundred and twenty-one patients received IT, 113
patients received TT (BRAFi,MEKi or combination), and 66
patients received IT and TT. Six patients in the TT group
were treated only with pan-RAF inhibitors. Thus, 95 patients
underwent chemotherapy (reference group). In the IT+TT
group, 17 (26%) patients received first IT and then upon
progression subsequently received TT, whereas 22 (33%)
patients were treated with anti-PD-1 antibodies in the EAP.
Before receiving IT or TT, approximately one-third of
the patients (n= 112) had been treated previously for
their advanced disease with alkylating chemotherapeutic
agents. Of these, only five patients received more than
two systemic treatments (Table 1).
Mutation status and patients’ characteristics
For all patients, histopathologic information such as
melanoma subtype, localization of primary tumor, and
tumor thickness was available. The presence or absence
of ulceration was obtainable in 67% of the patients.
Patients’ characteristics, demographics, and features of
primary metastatic melanoma with respect to mutation
status are listed in Table 2.
One hundred and eighty-one patients harbored a BRAF
mutation, 52 harbored an NRAS mutation, and 63 were
BRAF/NRAS wild type (BRAF/NRAS wt), whereas the
mutation status of 100 patients was unknown at the time
of inclusion.
Patients with BRAF mutant melanoma were generally
younger at the time of first diagnosis (median
age= 50 years) than patients without a BRAF mutation
(median age= 61 years, P< 0.001). Within the BRAF
mutated group (n= 181), primary melanoma of 69 (38%)
patients was found on the trunk, whereas 51 (32%)
melanomas were localized on the extremities. Fifty-eight
(32%) patients had nodular melanoma (NMM), 36 (20%)
patients had superficial spreading melanoma (SSM), and
two patients had had acrolentiginous melanoma (ALM)
(1%). In the NRAS mutant group (52), 15 (29%) mela-
nomas were located on the trunk and 20 on the extre-
mities (38%). Fifteen (29%) patients had NMM, five
(10%) had SSM, and five (10%) had ALM. In the double
wild-type group (63), 13 melanomas were located on the
trunk (21%) and 23 were located on the extremities
Table 1 Clinical characteristics of the four treatment groups
IT + TT
[n (%)]
IT
[n (%)]
TT
[n (%)]
Chemotherapy
[n (%)]
Age
Median 49.6 59.9 52.2 56.9
Breslow (mm)
0.01–1 3 (4.5) 14 (11.6) 15 (13.7) 14 (14.7)
1.01–2 15 (22.7) 17 (14) 18 (15.9) 15 (15.8)
2.01–4 17 (25.7) 25 (25.6) 30 (26.5) 20 (21.1)
>4 13 (19.7) 31 (25.6) 19 (16.8) 23 (24.2)
Unknown 18 (27.2) 34 (28) 31 (27.4) 23 (24.2)
CNS metastases
No 38 (57.6) 81 (66.9) 54 (47.8) 51 (53.7)
Yes 28 (42.4) 40 (33) 59 (53.2) 44 (46.3)
LDH
Elevated 9 (13.6) 23 (19.2) 26 (23) 27 (28.4)
Normal 25 (37.9) 56 (46.7) 45 (39.8) 45 (47.4)
Unknown 32 (48.5) 41 (34.1) 42 (37.2) 23 (24.2)
Mutation status
BRAF mut 53 (80.3) 13 (10.7) 101 (90.1) 14 (14.7)
NRAs mut 10 (15.2) 33 (27.3) 5 (4.5) 4 (4.2)
BRAF/NRAS wt 2 (3) 50 (41.3) 2 (1.8) 9 (9.5)
Unknown 1 (1.5) 7 (5.8) 4 (3.6) 59 (62.1)
BRAF wt/NRAS
unknown
0 (0) 18 (14.9) 0 (0) 9 (9.5)
Sex
Female 30 (45.5) 50 (41.3) 46 (40.7) 30 (31.6)
Male 36 (54.5) 71 (58.7) 67 (59.3) 65 (68.4)
Number of therapies (including adjuvant setting)
0 40 (60.6) 62 (51.2) 86 (76.1) 86 (90.5)
1 17 (25.8) 49 (40.5) 22 (19.5) 9 (9.5)
2 6 (9) 10 (8.3) 3 (2.6) 0 (0)
3 1 (1.5) 0 (0) 1 (0.9) 0 (0)
4 0 (0) 0 (0) 1 (0.9) 0 (0)
5 1 (1.5) 0 (0) 0 (0) 0 (0)
6 1 (1.5) 0 (0) 0 (0) 0 (0)
Ulceration
No 5 (7.6) 21 (17.4) 21 (18.6) 7 (7.4)
Yes 18 (27.3) 27 (22.3) 22 (19.5) 9 (6.5)
Unknown 43 (65.1) 73 (60.3) 70 (61.9) 79 (83.1)
Melanoma type
SSM 6 (9.2) 14 (11.6) 23 (20.4) 19 (20)
NMM 26 (40) 18 (14.9) 31 (27.4) 29 (30.5)
ALM 2 (3) 15 (12.4) 2 (1.8) 3 (3.2)
LMM 0 (0) 3 (2.5) 1 (0.9) 2 (2.1)
Desmoplastic 0 (0) 3 (2.5) 0 (0) 1 (1)
Amelanotic 2 (3) 4 (3.3) 2 (1.8) 2 (2.1)
Mucosal 1 (1.5) 7 (5.8) 3 (2.7) 5 (5.3)
Uveal 0 (0) 5 (4.1) 0 (0) 4 (4.2)
Othera 5 (7.7) 9 (7.4) 7 (6.2) 6 (6.3)
Unknown 23 (35.4) 43 (35.5) 44 (38.9) 24 (25.3)
ALM, acrolentiginous melanoma; CNS, central nervous system; IT, immunother-
apy; LDH, lactate dehydrogenase; mt, mutant; NMM, nodular melanoma;
SSM, superficial spreading melanoma; TT, targeted therapy; wt, wild type.
aPolypoid, ex naevo, not classified.
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(36.5%). Seven (11%) patients had NMM, six (10%) had
SSM, and nine (14%) had ALM (Table 2).
Survival data
The primary analysis included 395 patients who have received
either chemotherapy or IT or TT. The median follow-up
time was 26.3 months (interquartile range: 12.3–86.8 months).
The 1-year survival after first detection of distant
metastasis was 59% in the entire study cohort (n= 395),
amounting to 69% for patients treated with IT (n= 121),
50% for the TT group (n= 113), 85% for the IT+TT
group (n= 66), and 38% for patients treated with che-
motherapy (n= 95). Proportions for patients surviving
2 years were as follows: 30% in the entire study popula-
tion, 39% in IT, 20% in TT, 55% in those with both
IT+TT, and 15% in the reference group.
Compared with the reference group (n=95), there was a
statistically significant difference in mOS for patients treated
with IT or TT (n=300), with 7.4 months (95% CI: 6–8.5)
versus 14.6 months (95% CI: 12.2–18.2), respectively
(HR=0.40, P<0.0001) (Table 3). More specifically, mOS
was 16.7 months (n=121, 95%CI: 11.8–22.0) in the IT group,
11.2 months (n=113, 95% CI: 8.2–13) in the TT group, and
21.7 in those with IT+TT (n=66, 95% CI: 18.2–37.6)
(Fig. 1a and b). The difference remained statistically sig-
nificant for PFS in all groups, except IT (reference group
2.5 months, IT 2.15, IT/TT 5.4, and TT 7.3, P<0.0001)
(Fig. 1c and Table 4).
When survival data were subanalyzed for treatment-naive
patients (Fig. 2a), mOS was 7.1 for the reference (n= 86,
95% CI: 5.9–8.9) versus 17.8 (n= 188, 95% CI: 13.5–24.9,
HR= 0.39, P< 0.0001) for IT or TT. Separately, the mOS
of IT-treated patients was 41.4 months (n= 61), whereas
the mOS of TT-treated patients was 11.9 months (n= 86)
(Fig. 2b. In the TT group, 49 (57%) patients had brain
metastasis, whereas only 14 patients were in the IT group.
Survival data with respect to lactate dehydrogenase
levels
The LDH levels at stage IV disease were unknown in one-
third of the study cohort (35%). High LDH levels had a
significant negative impact in mOS only in patients treated
with TT (mOS 5 months for patients with high LDH levels
vs. mOS 12 months for patients with low LDH, HR=0.43,
P<0.01) (Fig. 3a). However, LDH levels seemed not to
influence the OS of IT-treated patients (mOS 11.8 for high
LDH vs. mOS 15.2, HR=0.62, P=0.11) (Fig. 3b).
Brain metastases patients
One hundred and seventy-one patients eventually developed
cerebral metastases at some point during stage IV disease. OS
of patients with brain metastases at stage IV was analyzed
separately. mOS of 61 patients with brain metastases was 8.1
versus 12.5 months for patients without evidence of brain
metastases at stage IV (n=334), showing a significant differ-
ence (HR=1.73, P<0.001) (Fig. 4a). When this subgroup
analysis was carried out according to treatment (reference vs.
IT vs. TT vs. IT+TT), there was no significant difference in
the reference group (Fig. 4b); there was a trend toward
improved survival in TT-treated patients (Fig. 4c); there was
no significant difference in the IT group (Fig. 4d); and there
was a statistically significant difference in mOS in IT+TT
(Fig. 4e) (Table 5).
Table 2 Patient demographics and primary melanoma
characteristics according to mutation status
Characteristics
BRAFV600mut
(n=181)
[n (%)]
NRASmut
(n=52)
[n (%)]
BRAF/
NRAS wt
(n=63)
[n (%)]
Age
Median 50.2 61.1 60.4
Sex
Male 103 (57) 31 (60) 43 (68)
Female 78 (43) 21 (40) 20 (32)
Histopathologic subtype
Superficial
spreading
melanoma
36 (20) 5 (10) 6 (10)
Nodular melanoma 58 (32) 15 (29) 7 (11)
Acral lentiginous 2 (1) 5 (10) 9 (14)
Lentigo maligna 1 (0.5) 1 (2) 2 (3)
Desmoplastic 0 (0) 0 (0) 3 (5)
Amelanotic 4 (2) 1 (2) 2 (3)
Mucosal 2 (1) 1 (2) 5 (8)
Uveal 0 (0) 0 (0) 1 (2)
Other 14 (8) 4 (8) 3 (5)
Unknown 63 (35) 20 (38) 25 (40)
Localization
Head/neck 30 (17) 10 (19) 13 (21)
Extremities 59 (32) 20 (38) 23 (36.5)
Trunk 69 (38) 15 (29) 13 (21)
Other 23 (13) 7 (14) 14 (21.5)
Breslow (mm)
0.01–1.0 21 (12) 6 (12) 6 (10)
1.01–2 35 (19) 7 (13) 11 (17)
2.01–4 46 (25) 14 (27) 15 (24)
>4 33 (18) 14 (27) 14 (22)
Unknown 46 (25) 11 (21) 17(27)
Union for International Cancer Control stage
0 0 (0) 0 (0) 0 (0)
I 32 (18) 10 (19) 12 (19)
II 43 (24) 15 (29) 16 (25)
III 74 (41) 18 (35) 18 (29)
IV 21 (11) 5 (9) 13 (21)
Unknown 11 (6) 4 (7) 4 (6)
Ulceration
No 27 (15) 7 (13) 17 (27)
Yes 45 (25) 11 (21) 12 (19)
Unknown 109 (60) 60 (66) 34 (54)
mut, mutant; wt, wild type.
Table 3 Median overall survival in months of study subgroups
Groups
Median overall
survival
(months) Hazard ratio P-value
Targeted therapy 11.2 0.57 <0.001
Immunotherapy 16.7 0.36 <0.001
Immunotherapy+ targeted
therapy
21.7 0.28 <0.001
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Hospitalization time
Themedian time spent in the hospital was investigated for all
patients in the subgroups. There was a statistically significant
difference in the hospitalization duration within the IT/TT
group compared with standard chemotherapy (Table 6).
Discussion
In the current study, we report on the survival data of 395
stage IV melanoma patients treated with kinase inhibitors
(BRAF or/and MEK) and checkpoint inhibitors (ipili-
mumab and pembrolizumab/nivolumab) compared with a
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historical control in the same setting treated with stan-
dard chemotherapy. This cohort is well defined and the
clinical data are of high quality, being evaluated in a
standardized database, and were closely updated every
6 months for the Swiss Melanoma Registry project.
The strengths of our study include the thorough follow-
up, the quality of clinical data analyzed by independent
clinicians, and the inclusion of patients mostly outside of
a clinical trial protocol representing real-life data. To
date, this is the largest OS analysis comparing che-
motherapy with the new treatment modalities in a real-
life setting in metastatic melanoma patients.
The superior outcome of the modern therapies in a real-
world setting with a longer follow-up duration in com-
parison with previous reports could be confirmed. We
show that longer survival is possible with MAPK inhibi-
tors, with 1- and 2-year OS rates of 50 and 19.5%. In the
TT group, high LDH levels had a significantly negative
prognostic impact (P= 0.035), suggesting that LDH is an
independent parameter associated with clinical outcome
in this patient population, which is consistent with pro-
spective published data of the BRAF/MEKi combination
treatment [39]. Frauchiger et al. [40] also confirmed the
predictive value of LDH (mOS for BRAFmut with nor-
mal LDH 14.2 vs. 6.95 months for high LDH). Although
survival was numerically different in our IT study cohort
within LDH low and high patients, the difference did not
reach statistical significance, probably due to the low
number of IT-treated.
For the checkpoint inhibitors (n=121), the 1- and 2-year OS
rates are 69 and 39%, respectively, which are in accordance
with the phase III clinical trials and recently published data
from the ipilimumab EAP [7,8,11,36,41,42]. However, our
checkpoint inhibitor cohort included pembrolizumab-
treated patients as well (n=36, 30%), reflecting the high
1-year OS of 69% presented here. These results are also in
agreement with the recently published ‘real world’ results of
71.2% (95% CI: 71.1–71.3) from Germany [43]. The authors
commented that this increased survival probability might to
be because of the closer radiological follow-up in advanced
melanoma patients in Germany and Switzerland every
6 months, which enables an early-stage diagnosis and early
initiation of treatment.
Table 4 Median progression-free survival in months of study
subgroups
Groups
Median
progression-free
survival (months) Hazard ratio P-value
Targeted therapy 7.3 0.39 <0.001
Immunotherapy 2.15 0.96 0.84
Immunotherapy+ targeted
therapy
5.4 0.60 <0.01
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41.4 months (n=61), whereas the mOS of TT-treated patients was 11.9 months. IT, immunotherapy; mOS, median overall survival; OS, overall
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The low PFS of 5.4 months in the IT/TT group com-
pared with chemotherapy (PFS= 2.5 months) can be
explained by the high number of patients treated with
ipilimumab in this group, influencing the PFS rates.
Accordingly, we report a low PFS (2.15 months) within
the IT group, whereas the PFS of TT patients (n= 113)
was 7.3 months. This is, however, comparable with the
median PFS in the ipilimumab-treated arm in the
Keynote 006 trial (mPFS 2.8 months) [31]. Only 30% of
the patients in the IT group had received pem-
brolizumab (either first or second line), which, despite
having influenced the mOS rates, was not the case for the
median PFS. In addition, and as is known, patients in
clinical trials are commonly filtered (Eastern Cooperative
Oncology Group status 0 or 1), often have normal LDH
levels, and have no symptomatic brain metastasis as brain
metastases are typically an exclusion criterion from clin-
ical trials. A separate subgroup classification of ipilimu-
mab and pembrolizumab was not performed because of
the small number of pembrolizumab-treated patients.
However, the development of new lesions in patients
receiving ipilimumab may not always indicate progressive
disease or treatment failure, reflecting the concept of
pseudoprogression, and may not correspond to the some-
times long-lasting responses in a minority of those patients.
To overcome this problem, new immune RECIST criteria
immune-related response criteria that provide a better
correlation between OS and response were proposed [44].
The study also investigated the survival of patients with
the presence of brain metastasis at stage IV disease and
found a superior outcome to those without as expected
(n= 334, mOS 8.1 months, vs. mOS 12.5 months’
P= 0.00065). These survival outcomes in brain-
metastasis melanoma patients are by far superior to the
4-month survival data reported in the literature [45,46].
This difference can be explained by the fact that the
majority of patients with brain metastasis in our study
received subsequent IT or TT after surgery or irradia-
tion, which clearly confounded the results [47,48]. We
observed a nonsignificant trend toward an improved
survival in patients with brain metastases treated with
TT (P= 0.06) and a significant survival benefit in those
treated with IT+TT. Nevertheless, these results should
be interpreted with caution because of the low numbers
of patients analyzed by treatment. Combining systemic
modern therapies for melanoma with conventional
treatment of brain metastasis is a field that requires fur-
ther investigation and large prospective trials are needed
to guide future clinical management of this poor-
prognosis group.
Another secondary endpoint of our study was to detect any
difference in the hospitalization time between patients treated
with checkpoint inhibitors or TT and those with standard
chemotherapy (reference group), reflecting differences in
treatment-association costs. A statistically significant difference
was reported (P=0.01 inTT andP=0.007 in IT), despite the
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(a, b) Elevated LDH levels had a significantly negative impact on mOS only in patients treated with TT, but not in IT-treated patients. IT, immunotherapy;
LDH, lactate dehydrogenase; mOS, median overall survival; TT, targeted therapy.
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(a) mOS in patients with brain metastasis at stage IV (b–e): Subanalysis in the brain-metastasis population according to treatment (reference vs. IT vs.
TT vs. IT + TT). There was a trend toward improved survival in TT-treated patients and a statistically significant difference in mOS in the IT+ TT group
(P=0.32, 0.42, 0.06, and 0.003, respectively). CNS, central nervous system; IT, immunotherapy; mOS, median overall survival; OS, overall survival;
TT, targeted therapy.
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presence of sometimes severe immune-related adverse events
(e.g. autoimmune-colitis or hypophysitis) documented with
ipilimumab. Consistently, and according to a retrospective-
single-center English cohort of patients (n=110) treated
with ipilimumab, immune-related adverse events do not
represent a significant expense in comparison with the drug
cost itself [49].
There are clear limitations in our study, including the
retrospective setting, with the potential selection bias or
time effects. However, patients from different sites
including university and nonuniversity hospitals in
Switzerland were included, minimizing the risk that the
current results are confounded by patient selection or
site-specific influences. At the time of the study design
and data collection, only ipilimumab (initially in the
second-line setting and as of end of 2014, in the first-line
setting) and BRAFi monotherapy was approved in
Switzerland for the treatment of metastatic melanoma,
which might have biased our results. Pembrolizumab
was not approved as first-line treatment until May 2016,
followed by the approval of combined nivolumab and
ipilimumab in summer 2016.
Because of this fact, ∼ 30% (n= 117) of the patients in the
IT or the TT group in our study had been pre-treated for
their advanced disease with chemotherapy. Also, when
analyzing the survival outcomes in treatment-naive
patients, there was again a significant difference in the
IT or the TT group (mOS 7.1 reference vs. 41 in the IT
group and 11.9 in the TT group). The reported mOS for
the TT group is consistent with the 13.6 months reported
in the literature [50]. The fact that the majority of
patients under TT develop resistance over time explains
this difference between IT and TT. However, resistance
after the initial response to anti-PD-1 has been reported
recently [51,52].
Furthermore and although we calculated survival out-
comes in treatment-naive patients (n=274), we did
not differentiate survival data between first-line and
second-line or third-line treatments because of the
inadequate number of patients.
This study confirms the superior outcome of IT-treated
and TT-treated advanced melanoma patients in a real-
life setting; however, a safe head-to-head comparison
between IT and TT cannot be made. Yet, we did analyze
a small subgroup of patients who had both IT+TT,
which suggested that the patients who benefit from both
treatments might benefit even more from the new drugs.
In this context, prospective clinical trials will further
elucidate optimal sequencing to improve patients’
counseling. A phase III clinical trial investigating this
issue is currently ongoing [53].
Conclusion
Treatment with checkpoint and kinase inhibitors beyond
clinical trials significantly improves the mOS in a real-life
setting including those patients with brain metastases.
These data confirm that national melanoma registries and
cancer statistics are useful for monitoring outcomes of
approved therapies or newly established treatment protocols
across multiple institutions and patient populations.
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